U.S. patent application number 09/989101 was filed with the patent office on 2002-12-12 for reovirus for the treatment of neoplasia.
Invention is credited to Coffey, Matthew C., Lee, Patrick W.K., Strong, James.
Application Number | 20020187125 09/989101 |
Document ID | / |
Family ID | 25430159 |
Filed Date | 2002-12-12 |
United States Patent
Application |
20020187125 |
Kind Code |
A1 |
Lee, Patrick W.K. ; et
al. |
December 12, 2002 |
Reovirus for the treatment of neoplasia
Abstract
Methods for treating neoplasia, by administering reovirus to a
Ras-mediated neoplasm, are disclosed. The reovirus is administered
so that it ultimately directly contacts cells of the neoplasm.
Human reovirus, non-human mammalian reovirus, and/or avian reovirus
can be used. If the reovirus is human reovirus, type 1 (e.g.,
strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain
Dearing or strain Abney), as well as other serotypes or strains of
reovirus can be used. Combinations of more than one type and/or
strain of reovirus can be used, as can reovirus from different
species of animal. Either solid neoplasms or hematopoietic
neoplasms can be treated.
Inventors: |
Lee, Patrick W.K.; (Calgary,
CA) ; Strong, James; (Calgary, CA) ; Coffey,
Matthew C.; (Calgary, CA) |
Correspondence
Address: |
Gerald F. Swiss
BURNS, DOANE, SWECKER & MATHIS, L.L.P.
P.O. Box 1404
Alexandria
VA
22313-1404
US
|
Family ID: |
25430159 |
Appl. No.: |
09/989101 |
Filed: |
November 21, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09989101 |
Nov 21, 2001 |
|
|
|
09569865 |
May 12, 2000 |
|
|
|
6344195 |
|
|
|
|
09569865 |
May 12, 2000 |
|
|
|
08911383 |
Aug 13, 1997 |
|
|
|
6110461 |
|
|
|
|
Current U.S.
Class: |
424/93.2 ;
435/235.1 |
Current CPC
Class: |
A61K 35/765 20130101;
C12N 7/00 20130101; A61P 35/00 20180101; C12N 2720/12261 20130101;
A61P 35/04 20180101; C12N 2720/12232 20130101; C12N 9/1205
20130101; A61P 35/02 20180101 |
Class at
Publication: |
424/93.2 ;
435/235.1 |
International
Class: |
A61K 048/00; C12N
007/00 |
Claims
What is claimed is:
1. A method of treating a Ras-mediated neoplasm in a mammal,
comprising administering to the neoplasm a reovirus in an amount
sufficient to result in reovirus-mediated oncolysis of cells of the
neoplasm.
2. The method of claim 1, wherein the reovirus is a human
reovirus.
3. The method of claim 2, wherein the reovirus is type 1.
4. The method of claim 2, wherein the reovirus is type 2.
5. The method of claim 2, wherein the reovirus is type 3.
6. The method of claim 1, wherein the reovirus is a non-human
reovirus.
7. The method of claim 6, wherein the reovirus is a mammalian
reovirus.
8. The method of claim 6, wherein the reovirus is an avian
reovirus.
9. The method of claim 1, wherein more than one type of reovirus is
administered.
10. The method of claim 1, wherein more than one strain of reovirus
is administered.
11. The method of claim 1, wherein the reovirus is a field
isolate.
12. The method of claim 1, wherein the reovirus is treated with a
protease prior to administration.
13. The method of claim 1, wherein the neoplasm is a solid
neoplasm.
14. The method of claim 3, wherein the reovirus is administered by
injection into the solid neoplasm.
15. The method of claim 13, wherein the reovirus is administered
intravenously into the mammal.
16. The method of claim 1, wherein the neoplasm is a hematopoietic
neoplasm.
17. The method of claim 16, wherein the reovirus is administered
intravenously into the mammal.
18. The method of claim 16, wherein the reovirus is administered
intraperitoneally into the mammal.
19. The method of claim 1, wherein the mammal is selected from the
group consisting of: mice, dogs, cats, sheep, goats, cows, horses,
pigs, and non-human primates.
20. The method of claim 1, wherein the mammal is a human.
21. The method of claim 1, wherein the neoplasm is pancreatic
cancer.
22. The method of claim 1, wherein the neoplasm is breast
cancer.
23. The method of claim 1, wherein the neoplasm is brain
cancer.
24. The method of claim 1, wherein the neoplasm is selected from
the group consisting of: lung cancer, prostate cancer, colorectal
cancer, thyroid cancer, renal cancer, adrenal cancer, liver cancer,
and leukemia.
25. The method of claim 1, wherein approximately 10.sup.3 to
10.sup.12 plaque forming units of reovirus are administered.
26. The method of claim 1, wherein the reovirus is administered in
a single dose.
27. The method of claim 1, wherein the reovirus is administered in
more than one dose.
28. The method of claim 1, wherein the reovirus is administered to
more than one neoplasm in the mammal.
29. The method of claim 1, wherein the ras-mediated neoplasm is
metastatic.
30. The method of claim 29, wherein the reovirus is administered to
a single solid neoplasm.
31. The method of claim 29, wherein the reovirus is administered
intravenously.
32. A method of treating a Ras-mediated neoplasm in a human,
comprising administering to the neoplasm a reovirus in an amount
sufficient to result in reovirus-mediated oncolysis of cells of the
neoplasm.
33. The method of claim 32, wherein the neoplasm is a solid
neoplasm.
34. The method of claim 33, wherein the solid neoplasm is
pancreatic cancer.
35. The method of claim 33, wherein the reovirus is administered by
injection into the solid neoplasm.
Description
BACKGROUND OF THE INVENTION
[0001] Normal cell proliferation is regulated by a balance between
growth-promoting proto-oncogenes and growth-constraining
tumor-suppressor genes. Tumorigenesis can be caused by genetic
alterations to the genome that result in the mutation of those
cellular elements that govern the interpretation of cellular
signals, such as potentiation of proto-oncogene activity or
inactivation of tumor suppression. It is believed that the
interpretation of these signals ultimately influences the growth
and differentiation of a cell, and that misinterpretation of these
signals can result in neoplastic growth (neoplasia).
[0002] Genetic alteration of the proto-oncogene Ras is believed to
contribute to approximately 30% of all human tumors (Wiessmuller,
L. and Wittinghofer, F. (1994), Cellular Signaling 6(3) :247-267;
Barbacid, M. (1987) A Rev. Biochem. 56, 779-827). The role that Ras
plays in the pathogenesis of human tumors is specific to the type
of tumor. Activating mutations in Ras itself are found in most
types of human malignancies, and are highly represented in
pancreatic cancer (80%), sporadic colorectal carcinomas (40-50%),
human lung adenocarcinomas (15-24%), thyroid tumors (50%) and
myeloid leukemia (30%) (Millis, N E et al. (1995) Cancer Res.
55:1444; Chaubert, P. et al. (1994), Am. J. Path. 144:767; Bos, J.
(1989) Cancer Res. 49:4682). Ras activation is also demonstrated by
upstream mitogenic signaling elements, notably by tyrosine receptor
kinases (RTKs). These upstream elements, if amplified or
overexpressed, ultimately result in elevated Ras activity by the
signal transduction activity of Ras. Examples of this include
overexpression of PDGFR in certain forms of glioblastomas, as well
as in c-erbB-2/neu in breast cancer (Levitzki, A. (1994) Eur. J.
Biochem. 226:1; James, P. W., et al. (1994) Oncogene 9:3601; Bos,
J. (1989) Cancer Res. 49:4682).
[0003] Current methods of treatment for neoplasia include surgery,
chemotherapy and radiation. Surgery is typically used as the
primary treatment for early stages of cancer; however, many tumors
cannot be completely removed by surgical means. In addition,
metastatic growth of neoplasms may prevent complete cure of cancer
by surgery. Chemotherapy involves administration of compounds
having antitumor activity, such as alkylating agents,
antimetabolites, and antitumor antibiotics. The efficacy of
chemotherapy is often limited by severe side effects, including
nausea and vomiting, bone marrow depression, renal damage, and
central nervous system depression. Radiation therapy relies on the
greater ability of normal cells, in contrast with neoplastic cells,
to repair themselves after treatment with radiation. Radiotherapy
cannot be used to treat many neoplasms, however, because of the
sensitivity of tissue surrounding the tumor. In addition, certain
tumors have demonstrated resistance to radiotherapy and such may be
dependent on oncogene or anti-oncogene status of the cell (Lee. J.
M. et al. (1993) PNAS 90:5742-5746; Lowe. S. W. et al. (1994)
Science, 266:807-810; Raybaud-Diogene. H. et al. (1997) J. Clin.
Oncology, 15(3):1030-1038). In view of the drawbacks associated
with the current means for treating neoplastic growth, the need
still exists for improved methods for the treatment of most types
of cancers.
SUMMARY OF THE INVENTION
[0004] The present invention pertains to methods for treating
neoplasia in a mammal, using reovirus. Reovirus is administered to
a neoplasm, in which an element of the Ras signaling pathway
(either upstream or downstream) is activated to an extent that
results in reovirus-mediated oncolysis of cells of the neoplasm.
The reovirus can be administered in a single dose or in multiple
doses; furthermore, more than one neoplasm in an individual mammal
can be treated concurrently. Both solid neoplasms and hematopoietic
neoplasms can be targeted. The reovirus is administered so that it
contacts cells of the mammal (e.g., by injection directly into a
solid neoplasm, or intravenously into the mammal for a
hematopoietic neoplasm). The methods can be used to treat neoplasia
in a variety of mammals, including mice, dogs, cats, sheep, goats,
cows, horses, pigs, and non-human primates. Preferably, the methods
are used to treat neoplasia in humans.
[0005] The methods of the invention provide an effective means to
treat neoplasia, without the side effects associated with other
forms of cancer therapy. Furthermore, because reovirus is not known
to be associated with disease, any safety concerns associated with
deliberate administration of a virus are minimized.
BRIEF DESCRIPTION OF THE DRAWING
[0006] The FIGURE is a depiction of the molecular basis of reovirus
oncolysis, in which the reovirus usurps the host cell Ras
signalling pathway.
DETAILED DESCRIPTION OF THE INVENTION
[0007] The invention pertains to methods of treating a neoplasm in
a mammal, by administering reovirus to the neoplasm. The name
reovirus (respiratory and enteric orphan virus) is a descriptive
acronym suggesting that these viruses, although not associated with
any known disease state in humans, can be isolated from both the
respiratory and enteric tracts (Sabin, A. B. (1959), Science
130:966). The mammalian reovirus consists of three serotypes: type
1 (strain Lang or T1L), type 2 (strain Jones, T2J) and type 3
(strain Dearing or strain Abney, T3D). The three serotypes are
easily identifiable on the basis of neutralization and
hemagglutinin-inhibition assays (Sabin, A. B. (1959), Science
130:966; Fields, B. N. et al. (1996), Fundamental Virology, 3rd
Edition, Lippincott-Raven; Rosen, L. (1960) Am. J. Hyg.71:242;
Stanley, N. F. (1967) Br. Med. Bull. 23:150).
[0008] Although reovirus is not known to be associated with any
particular disease, many people have been exposed to reovirus by
the time they reach adulthood (i.e., fewer than 25% in
children<5 years old, to greater than 50% in those 20-30 years
old (Jackson G. G. and Muldoon R. L. (1973) J. Infect. Dis.
128:811; Stanley N. F. (1974) In: Comparative Diagnosis of Viral
Diseases, edited by E. Kurstak and K. Kurstak, 385-421, Academic
Press, New York).
[0009] For mammalian reoviruses, the cell surface recognition
signal is sialic acid (Armstrong, G. D. et al. (1984), virology
138:37; Gentsch, J. R. K. and Pacitti, A. F. (1985), J. Virol.
56:356; Paul R. W. et al. (1989) Virology 172:382-385). Due to the
ubiquitous nature of sialic acid, reovirus binds efficiently to a
multitude of cell lines and as such can potentially target many
different tissues; however, there are significant differences in
susceptibility to reovirus infection between cell lines.
[0010] As described herein, Applicants have discovered that cells
which are resistant to reovirus infection became susceptible to
reovirus infection when transformed with a gene in the Ras pathway.
"Resistance" of cells to reovirus infection indicates that
infection of the cells with the virus did not result in significant
viral production or yield. Cells that are "susceptible" are those
that demonstrate induction of cytopathic effects, viral protein
synthesis, and/or virus production. Resistance to reovirus
infection was found to be at the level of gene translation, rather
than at early transcription: while viral transcripts were produced,
virus proteins were not expressed. Viral gene transcription in
resistant cells correlated with phosphorylation of an approximately
65 kDa cell protein, determined to be double-stranded RNA-activated
protein kinase (PKR), that was not observed in transformed cells.
Phosphorylation of PKR lead to inhibition of translation. When
phosphorylation was suppressed by 2-aminopurine, a known inhibitor
of PKR, drastic enhancement of reovirus protein synthesis occurred
in the untransformed cells. Furthermore, in a severe combined
immunodeficiency (SCID) mouse model in which tumors were created on
both the right and left hind flanks revealed that reovirus
significantly reduced tumor size when injected directly into the
right-side tumor; in addition, significant reduction in tumor size
was also noted on the left-side tumor which was not directly
injected with reovirus, indicating that the oncolytic capacity of
the reovirus was systemic as well as local.
[0011] These results indicated that reovirus uses the host cell's
Ras pathway machinery to downregulate PKR and thus reproduce. The
FIGURE depicts the usurpation of the host cell Ras signalling
pathway by reovirus. As shown in the FIGURE, for both untransformed
(reovirus-resistant) and EGFR-, Sos-, or ras-transformed
(reovirus-susceptible) cells, virus binding, internalization,
uncoating, and early transcription of viral genes all proceed
normally. In the case of untransformed cells, secondary structures
on the early viral transcripts inevitably trigger the
phosphorylation of PKR, thereby activating it, leading to the
phosphorylation of the translation initiation factor eIF-2.alpha.,
and hence the inhibition of viral gene translation. In the case of
EGFR-, Sos-, or ras-transformed cells, the PKR phosphorylation step
is prevented or reversed by Ras or one of its downstream elements,
thereby allowing viral gene translation to ensue. The action of Ras
(or a downstream element) can be mimicked by the use of
2-aminopurine (2-AP), which promotes viral gene translation (and
hence reovirus infection) in untransformed cells by blocking PKR
phosphorylation.
[0012] Based upon these discoveries, Applicants have developed
methods for treating neoplasms in mammals. Representative mammals
include mice, dogs, cats, sheep, a goats, cows, horses, pigs,
non-human primates, and humans. In a preferred embodiment, the
mammal is a human.
[0013] In the methods of the invention, reovirus is administered to
a neoplasm in the individual mammal. Representative types of human
reovirus that can be used include type 1 (e.g., strain Lang or
T1L); type 2 (e.g., strain Jones or T2J); and type 3 (e.g., strain
Dearing or strain Abney, T3D or T3A); other strains of reovirus can
also be used. In a preferred embodiment, the reovirus is strain
Dearing. Alternatively, the reovirus can be a non-human mammalian
reovirus (e.g., non-human primate reovirus, such as baboon
reovirus; equine; or canine reovirus), or a non-mammalian reovirus
(e.g., avian reovirus). A combination of different serotypes and/or
different strain of reovirus, such as reovirus from different
species of animal, can be used. The reovirus is
"naturally-occurring": that is, it can be isolated from a source in
nature and has not been intentionally modified by humans in the
laboratory. For example, the reovirus can be from a "field source":
that is, from a human patient. If desired, the reovirus can be
chemically or biochemically pretreated (e.g., by treatment with a
protease, such as chymotrypsin or trypsin) prior to administration
to the neoplasm. Such pretreatment removes the outer coat of the
virus and may thereby result in better infectivity of the
virus.
[0014] The neoplasm can be a solid neoplasm (e.g., sarcoma or
carcinoma), or a cancerous growth affecting the hematopoietic
system (a "hematopoietic neoplasm"; e.g., lymphoma or leukemia). A
neoplasm is an abnormal tissue growth, generally forming a distinct
mass, that grows by cellular proliferation more rapidly than normal
tissue growth. Neoplasms show partial or total lack of structural
organization and functional coordination with normal tissue. As
used herein, a "neoplasm", also referred to as a "tumor", is
intended to encompass hematopoietic neoplasms as well as solid
neoplasms. At least some of the cells of the neoplasm have a
mutation in which the Ras gene (or an element of the Ras signaling
pathway) is activated, either directly (e.g., by an activating
mutation in Ras) or indirectly (e.g., by activation of an upstream
element in the Ras pathway). Activation of an upstream element in
the Ras pathway includes, for example, transformation with
epidermal growth factor receptor (EGFR) or Sos. A neoplasm that
results, at least in part, by the activation of Ras, an upstream
element of Ras, or an element in the Ras signalling pathway is
referred to herein as a "Ras-mediated neoplasm". One neoplasm that
is particularly susceptible to treatment by the methods of the
invention is pancreatic cancer, because of the prevalence of
Ras-mediated neoplasms associated with pancreatic cancer. Other
neoplasms that are particularly susceptible to treatment by the
methods of the invention include breast cancer, brain cancer (e.g.,
glioblastoma), lung cancer, prostate cancer, colorectal cancer,
thyroid cancer, renal cancer, adrenal cancer, liver cancer, and
leukemia.
[0015] The reovirus is typically administered in a physiologically
acceptable carrier or vehicle, such as phosphate-buffered saline,
to the neoplasm. "Administration to a neoplasm" indicates that the
reovirus is administered in a manner so that it contacts the cells
of the neoplasm (also referred to herein as "neoplastic cells").
The route by which the reovirus is administered, as well as the
formulation, carrier or vehicle, will depend on the location as
well as the type of the neoplasm. A wide variety of administration
routes can be employed. For example, for a solid neoplasm that is
accessible, the reovirus can be administered by injection directly
to the neoplasm. For a hematopoietic neoplasm, for example, the
reovirus can be administered intravenously or intravascularly. For
neoplasms that are not easily accessible within the body, such as
metastases or brain tumors, the reovirus is administered in a
manner such that it can be transported systemically through the
body of the mammal and thereby reach the neoplasm (e.g.,
intrathecally, intravenously or intramuscularly). Alternatively,
the reovirus can be administered directly to a single solid
neoplasm, where it then is carried systemically through the body to
metastases. The reovirus can also be administered subcutaneously,
intraperitoneally, topically (e.g., for melanoma), orally (e.g.,
for oral or esophageal neoplasm), rectally (e.g., for colorectal
neoplasm), vaginally (e.g., for cervical or vaginal neoplasm),
nasally or by inhalation spray (e.g., for lung neoplasm).
[0016] The reovirus is administered in an amount that is sufficient
to treat-the neoplasm (e.g., an "effective amount"). A neoplasm is
"treated" when administration of reovirus to cells of the neoplasm
effects oncolysis of the neoplastic cells, resulting in a reduction
in size of the neoplasm, or in a complete elimination of the
neoplasm. The reduction in size of the neoplasm, or elimination of
the neoplasm, is generally caused by lysis of neoplastic cells
("oncolysis") by the reovirus. The effective amount will be
determined on an individual basis and may be based, at least in
part, on consideration of the type of reovirus; the individual's
size, age, gender; and the size and other characteristics of the
neoplasm. For example, for treatment of a human, approximately
10.sup.3 to 10.sup.12 plaque forming units (PFU) of reovirus can be
used, depending on the type, size and number of tumors present. The
reovirus can be administered in a single dose, or multiple doses
(i.e., more than one dose). The multiple doses can be administered
concurrently, or consecutively (e.g., over a period of days or
weeks). The reovirus can also be administered to more than one
neoplasm in the same individual.
[0017] The invention is further illustrated by the following
Exemplification.
EXEMPLIFICATION
Materials and Methods
Cells and Virus
[0018] Parental NIH-3T3 cell lines along with NIH-3T3 cells
transformed with a number of oncogenes were obtained from a variety
of sources. Parental NIH-3T3 and NIH-3T3 cells transfected with the
Harvey-ras (H-ras) and EJ-ras oncogenes were a generous gift of Dr.
Douglas Faller (Boston University School of Medicine). NIH-3T3
cells along with their Sos-transformed counterparts (designated
TNIH#5) were a generous gift of Dr. Michael Karin (University of
California, San Diego). Dr. H.-J. Kung (Case Western Reserve
University) kindly donated parental NIH-3T3 cells along with
NIH-3T3 cells transfected with the v-erbB oncogene (designated
THC-11). 2H1 cells, a derivative of the C3H 10T1/2 murine
fibroblast line, containing the Harvey-ras gene under the
transcriptional control of the mouse metallothionein-I promoter
were obtained from Dr. Nobumichi Hozumi (Mount Sinai Hospital
Research Institute). These 2H1 cells are conditional ras
transformant that express the H-ras oncogene in the presence of 50
.mu.M ZnSO.sub.4. All cell lines were grown in Dulbecco's modified
Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS).
[0019] The Dearing strain of reovirus serotype 3 used in these
studies was propagated in suspension cultures of L cells and
purified according to Smith (Smith, R. E. et al., (1969) Virology,
39:791-800) with the exception that .beta.-mercaptoethanol
(.beta.-ME) was omitted from the extraction buffer. Reovirus
labelled with [.sup.35S]methionine was grown and purified as
described by McRae and Joklik (McRae, M. A. and Joklik, W. K.,
(1978) Virology, 89:578-593). The particle/PFU ratio for purified
reovirus was typically 100/1.
Immunofluorescent analysis of reovirus infection
[0020] For the immunofluorescent studies the NIH-3T3, TNIH#5,
H-ras, EJ-ras, 2H1 (+/-ZnSO.sub.4), and THC-11 cells were grown on
coverslips, and infected with reovirus at a multiplicity of
infection (MOI) of .sup..about.10 PFU cell or mock-infected by
application of the carrier agent (phosphate-buffered saline, PBS)
to the cells in an identical fashion as the administration of virus
to the cells. At 48 hours postinfection, cells were fixed in an
ethanol/acetic acid (20/1) mixture for 5 minutes, then rehydrated
by sequential washes in 75%, 50% and 25% ethanol, followed by four
washes with phosphate-buffered saline (PBS). The fixed and
rehydrated cells were then exposed to the primary antibody (rabbit
polyclonal anti-reovirus type 3 serum diluted 1/100 in PBS)
[antiserum prepared by injection of rabbits with reovirus serotype
3 in Freund's complete adjuvant, and subsequent bleedings] for 2
hours at room temperature. Following three washes with PBS, the
cells were exposed to the secondary antibody [goat anti-rabbit IgG
(whole molecule)-fluorescein isothiocyanate conjugate (FITC) [Sigma
ImmunoChemicals F-0382] diluted 1/100 in PBS containing 10% goat
serum and 0.005% Evan's Blue ] for 1 hour at room temperature.
Finally, the fixed and treated cells were washed three more times
with PBS and then once with double-distilled water, dried and
mounted on slides in 90% glycerol containing 0.1% phenylenediamine,
and viewed with a Zeiss Axiophot microscope on which Carl Zeiss
camera was mounted (the magnification for all pictures was
200.times.).
Radiolabelling of Reovirus-infected cells and Preparation of
Lysates
[0021] Confluent monolayers of NIH-3T3, TNIH#5, H-ras, EJ-ras, 2H1
(+/-ZnSO.sub.4), and THC-11 cells were infected with reovirus (MOI
.sup..about.10 PFU/cell). At 12 hours postinfection, the media was
replaced with methionine-free DMEM containing 10% dialyzed FBS and
0.1 mCi/ml [.sup.35S]methionine. After further incubation for 36
hours at 37.degree. C., the cells were washed in phosphate-buffered
saline (PBS) and lysed in the same buffer containing 1% Triton
X-100, 0.5% sodium deoxycholate and 1 mM EDTA. The nuclei were then
removed by low speed centrifugation and the supernatants were
stored at -70.degree. C. until use.
Preparation of Cytoplasmic Extracts for in vitro Kinase Assays
[0022] Confluent monolayers of the various cell lines were grown on
96 well cell culture plaques. At the appropriate time postinfection
the media was aspirated off and the cells were lysed with a buffer
containing 20 mM HEPES [pH 7.4], 120 mM KCl, 5 mM MgCl.sub.2, 1 mM
dithiothreitol, 0.5% Nonidet P-40, 2 .mu.g/ml leupeptin, and 50
.mu.g/ml aprotinin. The nuclei were then removed by low-speed
centrifugation and the supernatants were stored at -70.degree. C.
until use.
[0023] Cytoplasmic extracts were normalized for protein
concentrations before use by the Bio-Rad protein microassay method.
Each in vitro kinase reaction contained 20 .mu.l of cell extract,
7.5 .mu.l of reaction buffer (20 mM HEPES [pH 7.4], 120 mM KCl, 5
mM MgCl.sub.2, 1 mM dithiothreitol, and 10% glycerol) and 7.0 .mu.l
of ATP mixture (1.0 .mu.Ci[.gamma.-.sup.32P]ATP in 7 .mu.l of
reaction buffer), and was incubated for 30 minutes at 37.degree. C.
(Mundschau, L. J., and Faller, D. V., J. Biol. Chem.,
267:23092-23098 (1992)). Immediately after incubation the labelled
extracts were either boiled in Laemmli SDS-sample buffer or were
either precipitated with agarose-poly(I)poly(C) beads or
immunoprecipitated with an anti-PKR antibody.
Agarose poly(I)poly(C) Precipitation
[0024] To each in vitro kinase reaction mixture, 30 .mu.l of a 50%
Ag poly(I)poly(C) Type 6 slurry (Pharmacia LKB Biotechnology) was
added, and the mixture was incubated at 4.degree. C. for 1 h. The
Ag poly(I)poly(C) beads with the absorbed, labelled proteins were
then washed four times with was buffer (20 mM HEPES [7.5 pH], 90 mM
KCl, 0.1 mM EDTA, 2 mM dithiothreitol, 10% glycerol) at room
temperature and mixed with 2.times.Laemmli SDS sample buffer. The
beads were then boiled for 5 min, and the released proteins were
analyzed by SDS-PAGE.
Polymerase Chain Reaction
[0025] Cells at various times postinfection were harvested and
resuspended in ice cold TNE (10 mM Tris [pH 7.8], 150 mM NaCl, 1 mM
EDTA) to which NP-40 was then added to a final concentration of 1%.
After 5 minutes, the nuclei were pelleted and RNA was extracted
from the supernatant using the phenol:chloroform procedure. Equal
amounts of total cellular RNA from each sample were then subjected
to RT-PCR (Wong, H., et al., (1994) Anal. Biochem., 223:251-258)
using random hexanucleotide primers (Pharmacia) and RTase
(GIBCO-BRL) according to the manufacturers' protocol. The cDNA's
from the RT-PCR step was then subjected to selective amplification
of reovirus s1 cDNA using the primer
5'-AATTCGATTTAGGTGACACTATAGCTATTGGTC- GGATG-3' (SEQ ID NO:1) and
5'-CCCTTTTGACAGTGATGCTCCGTTATCACTCG-3' (SEQ ID NO:2) that amplify a
predicted 116 bp fragment. These primer sequences were derived from
the S1 sequence determined previously (Nagata, L., et al.,(1984)
Nucleic Acids Res., 12:8699-8710). The GAPDH primers (Wong, H., et
al., (1994) Anal. Biochem., 223:251-258), 5'-CGGAGTCAACGGATTTGGTCG-
TAT-3' (SEQ ID NO:3) and 5'-AGCCTTCTCCATGGTGGTGAAGAC-3' (SEQ ID
NO:4) were used to amplify a predicted 306 bp GAPDH fragment which
served as a PCR and gel loading control. Selective amplification of
the s1 and GAPDH cDNA's was performed using Taq DNA polymerase
(GIBCO-BRL) according to the manufacturers' protocol using a Perkin
Elmer Gene Amp PCR system 9600. PCR was carried out for 28 cycles
with each consisting of a denaturing step for 30 seconds at
97.degree. C., annealing step for 45 seconds at 55.degree. C., and
polymerization step for 60 seconds at 72.degree. C. PCR products
were analyzed by electrophoresis through an ethidium
bromide-impregnated TAE-2% agarose gel and photographed under
ultra-violet illumination with Polaroid 57 film.
Immunoprecipitation and SDS-PAGE Analysis
[0026] Immunoprecipitation of .sup.35S-labelled reovirus-infected
cell lysates with anti-reovirus serotype 3 serum was carried out as
previously described (Lee, P. W. K. et al. (1981) Virology,
108:134-146). Immunoprecipitation of .sup.32P-labelled cell lysates
with an anti-PKR antibody (from Dr. Michael Mathews, Cold Spring
Harbor) was similarly carried out. Immunoprecipitates were analyzed
by discontinuous SDS-PAGE according to the protocol of Laemmli
(Laemmli, U. K., (1970) Nature, 227:680-685).
EXAMPLE 1
Activated Intermediates in the Ras Signalling Pathway Augment
Reovirus Infection Efficiency
[0027] It was previously shown that 3T3 cells and their derivatives
lacking epidermal growth factor receptors (EGFR) are poorly
infectible by reovirus, whereas the same cells transformed with
either EGFR or v-erb B are highly susceptible as determined by
cytopathic effects, viral protein synthesis, and virus output
(Strong, J. E. et al.,(1993) Virology, 197:405-411; Strong, J. E.
and Lee, P. W. K., (1996) J. Virol., 70:612-616).
[0028] To determine whether downstream mediators of the EGFR signal
transduction pathway may be involved, a number of different NIH
3T3-derived, transformed with constitutively activated oncogenes
downstream of the EGFR, were assayed for relative susceptibility to
reovirus infection. Of particular interest were intermediates in
the ras signalling pathway (reviewed by Barbacid, M., Annu. Rev.
Biochem., 56:779-827 (1987); Cahill, M. A., et al., Curr. Biol.,
6:16-19 (1996). To investigate the Ras signalling pathway, NIH 3T3
parental cell lines and NIH 3T3 lines transfected with activated
versions of Sos (Aronheim, A., et al.,(1994) Cell, 78:949-961) or
ras (Mundschau, L. J. and Faller, D. V., (1992) J. Biol. Chem.,
267:23092-23098) oncogenes were exposed to reovirus, and their
capacity to promote viral protein synthesis was compared.
[0029] Detection of viral proteins was initially carried out using
indirect immunofluorescent microscopy as described above. The
results indicated that whereas the NIH 3T3 cells adopted a
typically flattened, spread-out morphology with marked contact
inhibition, the transformed cells all grew as spindle-shaped cells
with much less contact inhibition. On comparing the uninfected
parental cell lines with the various transformed cell lines, it was
apparent that the morphology of the cells was quite distinct upon
transformation. Upon challenge with reovirus, it became clear that
parental NIH 3T3 line was poorly infectible (<5%), regardless of
the source of the parental NIH 3T3 line. In contrast, the
transfected cell lines each demonstrated relatively pronounced
immunofluorescence by 48 hours postinfection (data not shown).
[0030] To demonstrate that viral protein synthesis was more
efficient in the Sos- or Ras-transformed cell lines, cells were
continuously labeled with [.sup.35S]-methionine from 12 to 48 hr
postinfection and the proteins were analyzed by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), as described
above.
[0031] The results showed clearly that the levels of viral protein
synthesis were significantly higher in the Sos- or Ras-transformed
cells than in parental NIH 3T3 cells. The identities of the viral
bands were confirmed by immunoprecipitation of the labeled proteins
with polyclonal anti-reovirus antibodies. Since the uninfected NIH
3T3 cells and their transformed counterparts displayed comparable
levels of cellular protein synthesis and doubling times (data not
shown), the observed difference in the level of viral protein
synthesis could not be due to intrinsic differences in growth rates
or translation efficiencies for these cell lines.
EXAMPLE 2
Enhanced Infectibility Conferred by Activated Oncogenes is Not Due
to Long-term Transformation
[0032] To determine whether the differences in susceptibility may
be the result of long-term effects of transformation, or the result
of the activated oncogene itself, a cell line expressing a
zinc-inducible cellular Harvey-ras (c-H-ras) gene was tested for
susceptibility to reovirus infectibility, as described above. These
cells, called 2H1, were derived from the C3H 10T1/2 cell line which
is poorly infectible by reovirus (data not shown), and carry the
c-H-ras gene under the control of the mouse metallothionine-I
promoter (Trimble, W. S. et al. (1986) Nature, 321:782-784).
[0033] Cells were either mock-treated or pretreated with 50 .mu.M
ZnSO.sub.4 18 hours prior to infection or mock-infection
(administration of carrier agent), followed by indirect
immunofluorescent analysis of these cells at 48 hours postinfection
or mock-infection.
[0034] The results (not shown) demonstrated that uninduced cells
were poorly infectible (<8%) whereas those induced for only 18
hours were much more susceptible (>40%). Enhanced viral protein
synthesis in the Zn-induced 2H1 cells was further confirmed by
metabolic labeling of the cells with [.sup.35S]methionine followed
by SDS-PAGE analysis of virus-specific proteins (not shown).
[0035] Based on these observations, the augmentation of reovirus
infection efficiency in the transformed cells is a direct result of
the activated oncogene product(s), and not due to other factors
such as aneuploidy often associated with long-term transformation,
or other accumulated mutations that may be acquired under a
chronically transformed state (e.g., p53 or myc activation).
EXAMPLE 3
Viral Transcripts are Generated but Not Translated in
Reovirus-Resistant NIH 3T3 Cells
[0036] The step at which reovirus infection is blocked in
nonsusceptible NIH 3T3 cells was also identified. Because virus
binding and virus internalization for nonsusceptible cells were
comparable to those observed for susceptible cells (Strong, J. E.
et al., (1993) Virology, 197:405-411), the transcription of viral
genes was investigated.
[0037] The relative amounts of reovirus S1 transcripts generated in
NIH 3T3 cells and the Ras-transformed cells during the first 12
hours of infection were compared after amplification of these
transcripts by polymerase chain reaction (PCR), as described above.
The results demonstrated that the rates of accumulation of S1
transcripts in the two cell lines were similar, at least up to 12
hours postinfection. Similar data were obtained when rates of
accumulation of other reovirus transcripts were compared (data not
shown). These results demonstrate that infection block in
nonsusceptible cells is not at the level of transcription of viral
genes, but rather, at the level of translation of the
transcripts.
EXAMPLE 4
A 65 kDa Protein is Phosphorylated in Reovirus-treated NIH 3T3
Cells but Not in Reovirus-infected Transformed Cells
[0038] Because viral transcripts were generated, but not
translated, in NIH 3T3 cells, it was investigated whether the
double-stranded RNA (dsRNA)-activated kinase, PKR, is activated
(phosphorylated) in these cells (for example, by S1 mRNA
transcripts which have been shown to be potent activators of PKR
((Bischoff, J. R. and Samuel, C. E., (1989) Virology, 172:106-115),
which in turn leads to inhibition of translation of viral genes.
The corollary of such a scenario would be that in the case of the
transformed cells, this activation is prevented, allowing viral
protein synthesis to ensue.
[0039] NIH 3T3 cells and v-erbB- or Ras-transformed cells
(designated THC-11 and H-ras, respectively) were treated with
reovirus (i.e., infected) or mock-infected (as above), and at 48
hours post treatment, subjected to in vitro kinase reactions,
followed by autoradiographic analysis as described above.
[0040] The results clearly demonstrated that there was a distinct
phosphoprotein migrating at approximately 65 kDa, the expected size
of PKR, only in the NIH 3T3 cells and only after exposure to
reovirus. This protein was not labeled in the lysates of either the
uninfected transformed cell lines or the infected transformed cell
lines. Instead, a protein migrating at approximately 100 kDa was
found to be labeled in the transformed cell lines after viral
infection. This protein was absent in either the preinfection or
the postinfection lysates of the NIH 3T3 cell line, and was not a
reovirus protein because it did not react with an anti-reovirus
serum that precipitated all reovirus proteins (data not shown). A
similar 100 kDa protein was also found to be .sup.32P-labeled in in
vitro kinase reactions of postinfection lysates of the
Sos-transformed cell lines (data not shown).
[0041] That intermediates in the Ras signalling pathway were
responsible for the lack of phosphorylation of the 65 kDa protein
was further confirmed by the use of the 2H1 cells which contain a
Zn-inducible Ras oncogene. Uninduced 2H1 cells (relatively
resistant to reovirus infection, as shown above), were capable of
producing the 65 kDa phosphoprotein only after exposure to virus.
However, 2H1 cells subjected to Zn-induction of the H-Ras oncogene
showed significant impairment of the production of this
phosphoprotein. This impairment coincided with the enhancement of
viral synthesis. These results therefore eliminated the possibility
that the induction of the 65 kDa phosphoprotein was an NIH
3T3-specific event, and clearly established the role of Ras in
preventing (or reversing) induction of the production of this
phosphoprotein. The Zn-induced 2H1 cells did not produce the 100
kDa phosphoprotein seen in the infected, chronically transformed
H-Ras cells.
EXAMPLE 5
Induction of Phosphorylation of the 65 kDa Protein Requires Active
Viral Transcription
[0042] Since production of the 65 kDa phosphoprotein occurred only
in cells that were resistant to reovirus infection, and only after
the cells were exposed to reovirus, it was investigated whether
active viral transcription was required for production of the 68
kDa phosphoprotein. Reovirus was UV-treated to inactivate its
genome prior to administration of the reovirus to NIH 3T3 cells.
For UV-treatment, reovirus was suspended in DMEM to a concentration
of approximately 4.times.10.sup.8 PFU/mL and exposed to short-wave
(254 nm) UV light for 20 minutes. UV-inactivated virus were
non-infectious as determined by lack of cytopathic effects on mouse
L-929 fibroblasts and lack of viral protein synthesis by methods of
[.sup.35S]-methionine labelling as previously described. Such UV
treatment abolished viral gene transcription, as analyzed by PCR,
and hence viral infectivity (data not shown). The cells were then
incubated for 48 hours, and lysates were prepared and subjected to
in vitro .sup.32P-labeling as before. The results showed that NIH
3T3 cells infected with untreated reovirus produced a prominent 65
kDa .sup.32P-labelled band not found in uninfected cells. Cells
exposed to UV-treated reovirus behaved similarly to the uninfected
control cells, manifesting little phosphorylation, of the 65 kDa
protein. Thus, induction of the phosphorylation of the 65 kDa
phosphoprotein is not due to dsRNA present in the input reovirus;
rather, it requires de novo transcription of the viral genes,
consistent with the identification of the 65 kDa phosphoprotein as
PKR.
EXAMPLE 6
Identification of the 65 kDa Phosphoprotein as PKR
[0043] To determine whether the 65 kDa phosphoprotein was PKR, a
dsRNA binding experiment was carried out in which poly(I)-poly(c)
agarose beads were added to .sup.32P-labeled lysates, as described
above. After incubation for 30 minutes at 4.degree. C., the beads
were washed, and bound proteins were released and analyzed by
SDS-PAGE. The results showed that the 65 kDa phosphoprotein
produced in the postinfection NIH 3T3 cell lysates was capable of
binding to dsRNA; such binding is a well-recognized characteristic
of PKR. In contrast, the 100 kDa phosphoprotein detected in the
infected H-ras-transformed cell line did not bind to the
Poly(I)-poly(c) agarose. The 65 kDa phosphoprotein was also
immunoprecipitable with a PKR-specific antibody (provided by Dr.
Mike Mathews, Cold Spring Harbor Laboratory), confirming that it
was indeed PKR.
EXAMPLE 7
2-aminopurine Treatment of NIH 3T3 Cells Confers Enhanced
Infectibility
[0044] If PKR phosphorylation is responsible for the shut-off of
viral gene translation in NIH-3T3 cells, and one of the functions
of the activated oncogene product(s) in the transformed cells is
the prevention of this phosphorylation event, then inhibition of
PKR phosphorylation in NIH-3T3 cells by other means (e.g. drugs)
should result in the enhancement of viral protein synthesis, and
hence infection, in these cells. To test this idea, 2-aminopurine
was used. This drug has been shown to possess relatively specific
inhibitory activity towards PKR autophosphorylation (Samuel, C. E.
and Brody, M., (1990) Virology, 176:106-113; Hu, Y. and Conway, T.
W. (1993), J. Interferon Res., 13:323-328). Accordingly, NIH 3T3
cells were exposed to 5 mM 2-aminopurine concurrently with exposure
to reovirus. The cells were labeled with [.sup.35S]methionine from
12 to 48 h postinfection, and lysates were harvested and analyzed
by SDS-PAGE.
[0045] The results demonstrated that exposure to 2-aminopurine
resulted in a significantly higher level of viral protein synthesis
in NIH 3T3 cells (not shown). The enhancement was particularly
pronounced after immunoprecipitating the lysates with an
anti-reovirus serum. These results demonstrate that PKR
phosphorylation leads to inhibition of viral gene translation, and
that inhibition of this phosphorylation event releases the
translation block. Therefore, intermediates in the Ras signalling
pathway negatively regulate PKR, leading to enhanced infectibility
of Ras-transformed cells.
[0046] Interferon .beta., known to induce PKR expression, was found
to significantly reduce reovirus replication in Ras-transformed
cells (data not shown).
EXAMPLE 8
In Vivo Oncolytic Capability of Reovirus
[0047] A severe combined immunodeficiency (SCID) host tumor model
was used to assess the efficacy of utilizing reovirus for tumor
reduction. Male and female SCID mice (Charles River, Canada) were
injected with v-erbB-transformed NIH 3T3 mouse fibroblasts
(designated THC-11 cells) in two subcutaneous sites overlying the
hind flanks. In a first trial, an injection bolus of
2.3.times.10.sup.5 cells in 100 .mu.l of sterile PBS was used. In a
second trial, an injection bolus of 4.8.times.10.sup.6 cells in 100
.mu.l PBS was used. Palpable tumors were evident approximately two
to three weeks post injection.
[0048] Reovirus serotype three (strain Dearing) was injected into
the right-side tumor mass (the "treated tumor mass") in a volume of
20 .mu.l at a concentration of 1.0.times.10.sup.9 plaque forming
units (PFU)/ml. The left-side tumor mass (the "untreated tumor
mass") was left untreated. The mice were observed for a period of
seven days following injection with reovirus, measurements of tumor
size were taken every two days using calipers, and weight of tumors
was measured after sacrifice of the animals. All mice were
sacrificed on the seventh day. Results are shown in Table 1.
1TABLE 1 Tumor Mass after Treatment with Reovirus Trial 1 (n = 8)
mean untreated tumor mass 602 mg mean treated tumor mass 284 mg
Trial 2 (n = 12) mean control tumor mass 1523.5 mg mean untreated
tumor mass 720.9 mg mean treated tumor mass 228.0 mg
[0049] The treated tumor mass was 47% of that of the untreated
tumor mass in trial 1, and 31.6% of the untreated tumor mass in
trial 2. These results indicated that the virus-treated tumors were
substantially smaller than the untreated tumors, and that there may
be an additional systemic effect of the virus on the untreated
tumor mass.
EXAMPLE 9
In Vivo Oncolytic Capability of Reovirus Against Human Breast
Cancer-Derived Cell Lines
[0050] In vivo studies were also carried out using human breast
carcinoma cells in a SCID mouse model. Female SCID mice were
injected with 1.times.10.sup.9 MDAMB468 cells in two subcutaneous
sites, overlying both hind flanks. Palpable tumors were evident
approximately two to four weeks post injection. Undiluted reovirus
serotype three (strain Dearing) was injected into the right side
tumor mass in a volume of 20 .mu.l at a concentration of
1.0.times.10.sup.10 PFU/ml. The following results were
obtained:
2TABLE 2 Tumor Mass After Treatment with Reovirus mean untreated
tumor mean treated tumor TREATMENT mass (left side) mass (right
side) Reovirus (N = 8) 29.02 g 38.33 g Control (N = 8) 171.8 g
128.54 g *Note: One of the control mice died early during the
treatment phase. None of the reovirus-treated mice died.
[0051] Although these studies were preliminary, it was clear that
the size of the tumors in the reovirus-treated animals was
substantially lower than that in the untreated animals. However,
the size of the tumors on the right (treated) side of the
reovirus-treated animals was slightly larger on average than the
left (untreated) side. This was unexpected but may be explained by
the composition of the mass being taken up by inflammatory cells
with subsequent fibrosis, as well as by the fact that these tumors
were originally larger on the right side on average than the left.
The histologic composition of the tumor masses is being
investigated. These results also support the systemic effect the
reovirus has on the size of the untreated tumor on the
contralateral slide of reovirus injection.
EXAMPLE 10
Susceptibility of Additional Human Tumors to Reovirus Oncolysis
[0052] In view of the in vivo results presented above, the
oncolytic capability observed in murine cells was investigated in
cell lines derived from additional human tumors.
A. Materials and Methods
Cells and Virus
[0053] All cell lines were grown in Dulbecco's modified Eagle's
medium (DMEM) containing 10% fetal bovine serum (FBS).
[0054] The Dearing strain of reovirus serotype 3 used in these
studies was propagated in suspension cultures of L cells and
purified according to Smith (Smith, R. E. et al., (1969) Virology,
39:791-800) with the exception that .beta.-mercaptoethanol
(.beta.-ME) was omitted from the extraction buffer. Reovirus
labelled with [.sup.35S]methionine was grown and purified as
described by McRae and Joklik (McRae, M. A. and Joklik, W. K.,
(1978) Virology, 89:578-593). The particle/PFU ration for purified
reovirus was typically 100/1.
Cytopathic Effects of Reovirus on Cells
[0055] Confluent monolayers of cells were infected with reovirus
serotype 3 (strain Dearing) at a multiplicity of infection (MOI) of
approximately 40 plaque forming units (PFU) per cell. Pictures were
taken at 36 hour postinfection for both reovirus-infected and
mock-infected cells.
Immunofluorescent Analysis of Reovirus Infection
[0056] For the immunofluorescent studies the cells were grown on
coverslips, and infected with reovirus at a multiplicity of
infection (MOI) of .sup..about.10 PFU/cell or mock-infected as
described above. At various times postinfection, cells were fixed
in an ethanol/acetic acid (20/1) mixture for 5 minutes, then
rehydrated by subsequential washes in 75%, 50% and 25% ethanol,
followed by 4 washes with phosphate-buffered saline (PBS). The
fixed and rehydrated cells were then exposed to the primary
antibody (rabbit polyclonal anti-reovirus type 3 serum diluted
1/100 in PBS) for 2 hr at room temperature. Following 3 washes with
PBS, the cells were exposed to the secondary antibody [goat
anti-rabbit IgG (whole molecule) fluorescein isothiocyanate (FITC)
conjugate diluted 1/100 in PBS containing 10% goat serum and 0.005%
Evan's Blue counterstain] for 1 hour at room temperature. Finally,
the fixed and treated cells were washed 3 more times with PBS,
followed by 1 wash with double-distilled water, dried and mounted
on slides in 90% glycerol containing 0.1% phenylenediamine, and
viewed with a Zeiss Axiophot microscope mounted with a Carl Zeiss
camera (magnification for all pictures was 200.times.).
Infection of Cells and Quantitation of Virus
[0057] Confluent monolayers of cells grown in 24-well plates were
infected with reovirus at an estimated multiplicity of 10 PFU/cell.
After 1 hour incubation at 37.degree. C., the monolayers were
washed with warm DMEM-10% FBS, and then incubated in the same
medium. At various times postinfection, a mixture of NP-40 and
sodium deoxycholate was added directly to the medium on the
infected monolayers to final concentrations of 1% and 0.5%,
respectively. The lysates were then harvested and virus yields were
determined by plaque titration on L-929 cells.
Radiolabelling of Reovirus-Infected Cells and Preparation of
Lysates
[0058] Confluent monolayers of cells were infected with reovirus
(MOI .sup..about.10 PFU/cell). At various times postinfection, the
media was replaced with methionine-free DMEM containing 10%
dialyzed PBS and 0.1 mCi/ml [.sup.35S]methionine. After further
incubation for 1 hour at 37.degree. C., the cells were washed in
phosphate-buffered saline (PBS) and lysed in the same buffer
containing 1% Triton X-100, 0.5% sodium deoxycholate and 1 mM EDTA.
The nuclei were then removed by low speed centrifugation and the
supernatants was stored at 70.degree. C. until use.
Immunoprecipitation and SDS-PAGE Analysis
[0059] Immunoprecipitation of [.sup.35S]-labelled reovirus-infected
cell lysates with anti-reovirus serotype 3 serum was carried out as
previously described (Lee, P. W. K. et al. (1981) Virology,
108:134-146). Immunoprecipitates were analyzed by discontinuous
SDS-PAGE according to the protocol of Laemmli (Laemmli, U. K.,
(1970) Nature, 227:680-685).
B. Breast Cancer
[0060] The c-erbB-2/neu gene encodes a transmembrane protein with
extensive homology to the EGFR that is overexpressed in 20-30% of
patients with breast cancer (Yu, D. et al. (1996) Oncogene
13:1359).Since it has been established herein that Ras activation,
either through point mutations or through augmented signaling
cascade elements upstream of Ras (including the c-erbB-2/neu
homologue EGFR) ultimately creates a hospitable environment for
reovirus replication, an array of cell lines derived from human
breast cancers were assayed for reovirus susceptibility. The cell
lines included MDA-MD-435SD (ATCC deposit HTB-129), MCF-7 (ATCC
deposit HTB-22), T-27-D (ATCC deposit HTB-133), BT-20 (ATCC deposit
HTB-19), HBL-100 (ATCC deposit HTB-124), MDA-MB-468 (ATCC deposit
HTB-132), and SKBR-3 (ATCC deposit HTB-30).
[0061] Based upon induction of cytopathic effects, and viral
protein synthesis as measured by radioactive metabolic labeling and
immunofluorescence as described above, it was found that five out
of seven of the tested breast cancers were susceptible to reovirus
infection: MDA-MB-435S, MCF-7, T-27-D, MDA MB-468, and SKBR-3 were
exquisitely sensitive to infection, while BT-20 and HBL-100
demonstrated no infectibility.
C. Brain Glioblastoma
[0062] Next a variety of cell lines derived from human brain
glioblastomas was investigated. The cell lines included A-172,
U-118, U-178, U-563, U-251, U-87 and U-373 (cells were a generous
gift from Dr. Wee Yong, University of Calgary).
[0063] Six out of seven glioblastoma cell lines demonstrated
susceptibility to reovirus infection, including U-118, U-178,
U-563, U-251, U-87 and U-373, while A-172 did not demonstrate any
infectibility, as measured by cytopathic effects,
immunofluorescence and [.sup.35S]-methionine labeling of reovirus
proteins.
D. Pancreatic Carcinoma
[0064] Cell lines derived from pancreatic cancer were investigated
for their susceptibility to reovirus infection. The cell lines
included Capan-1 (ATCC deposit HTB-79), BxPC3 (ATCC deposit
CRL-1687), MIAPACA-2(ATCC deposit CRL-1420), PANC-1 (ATCC deposit
CRL-1469), AsPC-1 (ATCC deposit CRL-1682) and Hs766T (ATCC deposit
HTB-134).
[0065] Five of these six cell lines demonstrated susceptibility to
reovirus infection including Capan-1, MIAPACA-2, PANC-1, AsPC-1 and
Hs766T, whereas BxPC3 demonstrated little infectability as assayed
by virus-induced cytopathological effects, immunofluorescence and
[.sup.35S]-labelling. Interestingly, four of the five cell lines
demonstrating susceptibility to reovirus oncolysis have been shown
to possess transforming mutations in codon 12 of the K-ras gene
(Capan-1, MIAPACA-2, PANC-1 and AsPC-1) whereas the one lacking
such susceptibility (BxPC3) has been shown to lack such a mutation
(Berrozpe, G., et al. (1994), Int. J. Cancer, 58:185-191). The
status of the other K-ras codons is currently unknown for the
Hs766T cell line.
Equivalents
[0066] Those skilled in the art will be able to recognize, or be
able to ascertain, using no more than routine experimentation, many
Equivalents to the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed by the
following claims.
* * * * *